Strong Interim Data for RAD 101 May Propel Future Trials
Radiopharm's RAD 101 achieved 90% concordance with MRI in brain metastases diagnosis, receiving FDA Fast Track Designation. Promising early follow-up data and upcoming analysis due in June could lead to pivotal testing, potentially impacting market perception positively.
View signal analysis